| INO-8000 / Inovio |
NCT02822079: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection |
|
|
| Recruiting | 1 | 32 | US | DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012, Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment | Mayo Clinic, Inovio Pharmaceuticals, National Cancer Institute (NCI) | Chronic Hepatitis, Hepatitis C Infection | 03/20 | | | |
NCT02772003: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection |
|
|
| Active, not recruiting | 1 | 33 | US | Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Rocakinogene Sifuplasmid, DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012 | National Cancer Institute (NCI), Inovio Pharmaceuticals | Chronic Hepatitis, Hepatitis C Infection | 03/20 | 03/25 | | |
| INO-1400 / Inovio |
NCT02327468: Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers |
|
|
| Recruiting | 1 | 54 | US | INO-1400, hTERT, INO-9012, IL-12 | Inovio Pharmaceuticals, Abramson Cancer Center of the University of Pennsylvania, University of North Carolina, Thomas Jefferson University, Wayne State University | Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Squamous Cell Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Cancer | 12/17 | 04/18 | | |
| bizalimogene ralaplasmid (VGX-3100) / Inovio |
NCT03603808: VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions |
|
|
| Active, not recruiting | 2 | 80 | US | Electroporation, electroporation therapy, EPT, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, VGX-3100, Laboratory Biomarker Analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, Inovio Pharmaceuticals | Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | 09/29 | 09/29 | | |
| rocakinogene sifuplasmid (INO-9012) / Inovio |
GT-30, NCT04251117: GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC |
|
|
| Active, not recruiting | 1/2 | 36 | US, RoW | GNOS-PV02, INO-9012, Pembrolizumab, CELLECTRA®2000 EP Device | Geneos Therapeutics | HCC | 08/23 | 06/25 | | |
NCT03502785 / 2018-000309-21: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma |
|
|
| Active, not recruiting | 1/2 | 35 | US | INO-5401, INO-9012, Atezolizumab, CELLECTRA™ 2000 | Inovio Pharmaceuticals | Urothelial Carcinoma | 12/24 | 12/24 | | |
NCT03491683: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) |
|
|
| Active, not recruiting | 1/2 | 52 | US | INO-5401, INO-9012, Cemiplimab, REGN2810, Radiation Therapy, Temozolomide | Inovio Pharmaceuticals | Glioblastoma | 12/24 | 12/24 | | |
|
NCT04367675: INO 5401 Vaccination in BRCA1/2 Mutation Carriers |
|
|
| Recruiting | 1b | 44 | US | INO-5401, INO-9012, Cellectra 2000 | University of Pennsylvania, Inovio Pharmaceuticals | BRCA1/2 Mutation | 12/25 | 12/25 | | |
NCT04015700: Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma |
|
|
| Active, not recruiting | 1 | 9 | US | Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics, GNOS-PV01, Vaccine, CELLECTRA®2000 EP Device supplied by Geneos Therapeutics, Plasmid encoded IL-12, INO-9012 | Washington University School of Medicine, Geneos Therapeutics, The Foundation for Barnes-Jewish Hospital | Glioblastoma | 05/22 | 12/24 | | |
| zenuzolac (VGX-1027) / GeneOne |
NCT04590547: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) |
|
|
| Active, not recruiting | 2 | 132 | Europe, US, RoW | GLS-1027, Placebo | GeneOne Life Science, Inc. | Pneumonitis, SARS-CoV Infection | 08/22 | 12/23 | | |
2021-002730-16: Safety, Tolerability, Efficacy and Dose Response of GLS-1027 in the Prevention of Sever Pneumonitis caused by COVID-19 |
|
|
| Not yet recruiting | 2 | 200 | Europe | GLS-1027, GLS-1027, Capsule | GeneOne Life Science Inc., GeneOne Life Science Inc. | Patients with SARS-CoV-2 infection, Patients with COVID-19, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| INO-3107 / Inovio |
NCT04398433: INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) |
|
|
| Completed | 1/2 | 32 | US | INO-3107, CELLECTRA™ 2000 | Inovio Pharmaceuticals | Respiratory Papillomatosis | 12/22 | 12/22 | | |
| AZD5396 / Inovio, AstraZeneca |
| Recruiting | 1 | 50 | US | dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device | Pablo Tebas, The Wistar Institute, AstraZeneca, Inovio Pharmaceuticals | Healthy Volunteers | 09/25 | 09/25 | | |
| INO-9112 / Inovio |
| No trials found |
| AZD8076 / AstraZeneca, Inovio |
| No trials found |
| INO-3106 / Inovio |
| No trials found |
